Volume 67, Issue 2, Pages (August 2017)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,

Copyright © 2016 McGraw-Hill Education. All rights reserved.

Chair: Pietro Lampertico Panel members:

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

The impact of hepatitis E in the liver transplant setting

Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs

Volume 50, Issue 4, Pages (April 2009)

Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”

R. Cavallo Clinical Microbiology and Infection

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Volume 51, Issue 6, Pages (December 2009)

The impact of hepatitis E in the liver transplant setting

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Volume 42, Issue 1, Pages (January 2005)

Immigration and viral hepatitis

Virological tools to diagnose and monitor hepatitis C virus infection

Natural history of hepatitis B

Suna Yapali, Nizar Talaat, Anna S. Lok

Stephanos J. Hadziyannis Journal of Hepatology

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results Bruno Roche, Didier Samuel Journal.

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

Volume 69, Issue 2, Pages (August 2018)

Volume 44, Pages S19-S24 (January 2006)

Volume 68, Issue 3, Pages (March 2018)

Volume 50, Issue 4, Pages (April 2009)

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? Neil Rajoriya,

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency Danny Ka-Ho Wong, Wai-Kay.

Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study M.-C. Tsai,

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

European Association for the Study of the Liver Journal of Hepatology

Volume 139, Issue 4, Pages e3 (October 2010)

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field? Andres Duarte-Rojo, Elizabeth Jenny Heathcote,

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

Genomic risk of hepatitis C-related hepatocellular carcinoma

Autophagy in the liver Journal of Hepatology

Volume 66, Issue 1, Pages (January 2017)

Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,

EASL Clinical Practice Guidelines: Wilson’s disease

Volume 44, Issue 2, Pages (February 2006)

Economics of chronic hepatitis B and hepatitis C

Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon.

Volume 42, Issue 3, Pages (March 2005)

EASL Clinical Practice Guidelines on hepatitis E virus infection

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised,

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Treatment of hepatitis B in patients with chronic kidney disease

Volume 59, Issue 4, Pages (October 2013)

Volume 50, Issue 4, Pages (April 2009)

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Volume 67, Issue 5, Pages (November 2017)

Immigration and viral hepatitis

Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability Markus Cornberg,

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Volume 63, Issue 1, Pages (July 2015)

Volume 51, Issue 2, Pages (August 2009)

Chronic hepatitis B in children and adolescents

Volume 62, Issue 4, Pages (April 2015)

Pathogenesis of cholestatic hepatitis C

HEPATITIS B VIRUS ; WHAT`S NEW

Chimeric mouse model of hepatitis B virus infection

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

Emmet B. Keeffe, Douglas T

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Presentation transcript:

Volume 67, Issue 2, Pages 370-398 (August 2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke Journal of Hepatology Volume 67, Issue 2, Pages 370-398 (August 2017) DOI: 10.1016/j.jhep.2017.03.021 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Natural history and assessment of patients with chronic HBV infection based upon HBV and liver disease markers. *Persistently or intermittently. °°HBV DNA levels can be between 2,000 and 20,000IU/ml in some patients without sings of chronic hepatitis. Journal of Hepatology 2017 67, 370-398DOI: (10.1016/j.jhep.2017.03.021) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Algorithm for the management of HBV infection. 1see definitions in text and Fig. 1. Journal of Hepatology 2017 67, 370-398DOI: (10.1016/j.jhep.2017.03.021) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Cumulative incidence of HBV resistance for lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (TBV), tenofovir (TDF) and tenofovir alafenamide (TAF) in pivotal trials in nucleos(t)ide-naïve patients with chronic hepatitis B. (Collation of currently available data – not from head-to-head studies). No evidence of resistance has been shown after 8 years of TDF treatment.69 Journal of Hepatology 2017 67, 370-398DOI: (10.1016/j.jhep.2017.03.021) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Week 12 and 24 stopping rules for HBeAg-positive and -negative patients treated with PegIFNα. These rules are based upon viral genotype, HBsAg and HBV levels. Journal of Hepatology 2017 67, 370-398DOI: (10.1016/j.jhep.2017.03.021) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions